Treatment Of Idiopathic Pulmonary Fibrosis
Publication Date: July 1, 2015
Last Updated: September 2, 2022
Treatment
For patients with IPF, the guideline committee recommends:
Clinicians NOT use imatinib. ( Moderate , S, M)
695
Clinicians NOT use warfarin anticoagulation in patients who do not have a known alternative indication for its use. ( Low , S, L)
695
Clinicians NOT use the combination therapy of N-acetylcysteine, azathioprine, and prednisone. ( Low , S, L)
695
Clinicians NOT use ambrisentan, a selective ER-A endothelin receptor antagonist, regardless of the presence or absence of PH. ( Low , S, L)
695
For patients with IPF, the guideline committee suggests:
Clinicians use nintedanib. ( Moderate , C, M)
695
Clinicians use pirfenidone. ( Moderate , C, M)
695
Clinicians NOT use sildenafil, a phosphodiesterase-5 inhibitor. ( Moderate , C, M)
695
Clinicians NOT use bosentan or macitentan, both dual ER-A and ER-B endothelin receptor antagonists. ( Low , C, L)
695
Clinicians NOT use N-acetylcysteine monotherapy. ( Low , C, L)
695
Clinicians use regular anti-acid treatment. ( Very low , C, VL)
695
Recommendation Grading
Overview
Title
Treatment Of Idiopathic Pulmonary Fibrosis
Authoring Organization
American Thoracic Society
Publication Month/Year
July 1, 2015
Last Updated Month/Year
October 4, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.
Target Patient Population
Patients with idiopathic pulmonary fibrosis
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D054990 - Idiopathic Pulmonary Fibrosis
Keywords
interstitial lung disease, Idiopathic pulmonary fibrosis (IPF), IPF, Pulmonary Fibrosis, ILD
Supplemental Methodology Resources
Methodology
Number of Source Documents
105
Literature Search Start Date
May 1, 2010
Literature Search End Date
July 1, 2014